Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.

Détails

ID Serval
serval:BIB_0EBF8A67EBB4
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.
Périodique
International journal of cardiology
Auteur(s)
Arroyo D., Gendre G., Schukraft S., Kallinikou Z., Müller O., Baeriswyl G., Stauffer J.C., Goy J.J., Togni M., Cook S., Puricel S.
ISSN
1874-1754 (Electronic)
ISSN-L
0167-5273
Statut éditorial
Publié
Date de publication
15/09/2017
Peer-reviewed
Oui
Volume
243
Pages
121-125
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article ; Randomized Controlled Trial
Publication Status: ppublish
Résumé
Data from randomized controlled trials have shown that the ABSORB BVS is non-inferior to Cobalt Chromium everolimus-eluting stents at 2years.
The EVERBIO II trial (Comparison of Everolimus- and Biolimus-Eluting Coronary Stents with Everolimus-Eluting Bioresorbable Vascular Scaffold) is a single-center, assessor-blind, randomized controlled trial enrolling 240 patients with an allocation ration of 1:1:1 conducted at University and Hospital Fribourg, Switzerland. The studied devices were an everolimus-eluting persistent polymer stent (EES), a biolimus-eluting stent with bioabsorbable polymer (BES) and a fully bioresorbable vascular scaffold (BVS). Clinical end points collected at 9months, 12months, and 2years, were academic research consortium defined composites, device thrombosis and target-vessel revascularization. Clinical follow-up at 2years was available in 96% (N=77) of patients in the EES group, in 100% (N=80) in the BES and 99% (N=77) in the BVS group. The device-oriented composite end point of cardiac death, target-vessel myocardial infarction and target-lesion revascularization occurred in 13 (16%) patients treated with EES, in 7 (9%) patients treated with BES and in 16 (21%) patients treated with BVS. There was no significant difference when the metallic stents were compared to the BVS (p=0.12). There was one late scaffold thrombosis throughout the trial in the BVS group, and no definite stent thrombosis in either EES or BES treated patients.
The current analysis shows no significant differences with regard to clinical outcomes at 2years between BVS and the best-in-class metallic DES. Event rates were numerically higher in BVS-treated patients. However, when BVS were compared to BES alone, the occurrence of device related adverse events was significantly increased.

Mots-clé
Absorbable Implants/trends, Aged, Coronary Restenosis/diagnostic imaging, Coronary Restenosis/surgery, Drug-Eluting Stents/trends, Everolimus/administration & dosage, Female, Fibrinolytic Agents/administration & dosage, Follow-Up Studies, Humans, Male, Middle Aged, Single-Blind Method, Sirolimus/administration & dosage, Sirolimus/analogs & derivatives, Time Factors, Tissue Scaffolds/trends, Treatment Outcome, Bioresorbable vascular scaffold, Coronary artery disease, Drug-eluting stent, Percutaneous coronary intervention
Pubmed
Web of science
Création de la notice
19/06/2017 8:46
Dernière modification de la notice
20/08/2019 13:35
Données d'usage